Similarly, treatment with NAV-2729, a direct inhibitor of ARF6 GTPase function13, reduced ARF6-GTP levels (Fig. S1h) and decreased cell viability in most of the human melanoma cells tested (Fig. S2d), although not as effectively as ARF6 silencing (Fig. 3e). This evidence concerns the gene ARF6 and melanoma.